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Abstract
Background: In contrast to rheumatoid arthritis (RA), no systematic investigation of diurnal variation has been carried
out in polymyalgia rheumatica (PMR). The aim of the study was to provide the often-requested documentation of the
24-h time course of clinical symptoms in PMR and relate them to concentrations during the day of melatonin,
inflammatory cytokines, and cortisol. Furthermore, the effects of 14 days of prednisolone treatment were studied.
Methods: Ten glucocorticoid-naive patients newly diagnosed with PMR and seven non-PMR control subjects were
studied for 24 h before treatment and during the 14th day of treatment with 20 mg/day of prednisolone. Global pain
and generalized muscle stiffness were monitored by using visual analogue scales, and blood was drawn repeatedly.
Results: In untreated patients, pain and stiffness peaked in the early morning, showing a plateau between 04:00 and
08:00, and then declined to a nadir at 16:00 (2P < 0.05). Plasma concentrations of interleukin (IL)-6, IL-8, tumor necrosis
factor (TNF)-α, IL-1β, and IL-4 varied with time in both groups (2P < 0.05) and peaked between 04:00 and 08:00.
Furthermore, except for IL-1β, concentrations of these cytokines and of IL-10 were higher throughout the 24-h
observation period in patients than in control subjects (2P < 0.05). Also, melatonin and cortisol were consistently higher
in patients (2P < 0.05) and varied with time (2P < 0.05), peaking around 02:00 and 08:00, respectively. In patients,
prednisolone abolished symptoms, normalized C-reactive protein, and reduced melatonin, IL-6, IL-8, and TNF-α
concentrations (2P < 0.05), while IL-10 increased between 10:00 and 14:00.
Conclusions: In PMR, key symptoms show diurnal variation. Furthermore, in PMR, concentrations of melatonin, several
pro- and anti-inflammatory cytokines, and cortisol are increased throughout the day and show diurnal variation, as also
seen in healthy subjects. The time courses and the inhibitory effects of prednisolone indicate that in PMR, as proposed
for RA, melatonin stimulates cytokine production, which in turn accounts at least partly for the symptoms. Furthermore,
overall, cortisol may downregulate cytokine production and symptoms. Stimulation of IL-10 secretion may participate
in the anti-inflammatory effects of prednisolone. These findings support use of chronotherapy in PMR and encourage
study of circadian variations in other inflammatory autoimmune diseases.
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Background
In rheumatoid arthritis (RA), key clinical symptoms and
findings show a circadian variation, with more promin-
ent joint swelling, stiffness, and pain occurring in the
early morning [1, 2]. Interestingly, within recent years, it
has been pointed out that, in RA, the diurnal variation
in symptoms coincides with and may be partly mediated
by a circadian variation in plasma concentrations of pro-
inflammatory cytokines [1–5]. Furthermore, it has been
proposed that, in RA, the pineal hormone and key chro-
nobiological marker melatonin regulates circadian cyto-
kine production, and it has been shown that plasma
concentrations of melatonin are higher in patients with
RA than in control subjects and peak a couple of hours
before cytokine concentrations [1–3]. However, cortisol,
which has a response to light that is opposite that of mela-
tonin and, accordingly, a different diurnal time course,
may counteract the inflammatory processes [1, 4].
Polymyalgia rheumatica (PMR) is the most common
chronic autoimmune rheumatic disease of the elderly
[6, 7]. For the most part, it is easily distinguished from
RA. However, in PMR, morning stiffness and aching
are also generally accepted core symptoms, as reflected
by the various sets of criteria defined for its diagnosis
[4, 6–10]. Nevertheless, although a circadian rhythm
seems obvious, no systematic investigation of the 24-h
variation of pain and stiffness in PMR has been published,
and such data are often requested [5, 11]. Furthermore,
while in both PMR [9, 12, 13] and RA [14] plasma con-
centrations of many cytokines, when measured at a single
time point in the morning, have been found to be higher
than in healthy subjects, in PMR the circadian courses of
cytokines and cortisol have not yet been determined in
controlled studies [11, 15]. Also, in contrast to RA, mela-
tonin concentrations have not been evaluated in PMR.
Thus, to add to the existing clinical evidence and to elu-
cidate possible pathophysiological mechanisms in PMR, in
the present study clinical symptoms and plasma concen-
trations of cytokines, melatonin, and cortisol were moni-
tored for 24 h in patients with PMR and healthy subjects.
Both groups were studied before and after 13 days of
glucocorticoid (GC) treatment, which is known to abolish
symptoms in patients with PMR [6–9, 12, 13, 16].
Methods
Subjects
Ten consecutively referred GC-naive patients newly di-
agnosed with PMR according to the criteria proposed by
Chuang and colleagues [6, 7, 10, 17], as well as seven
non-PMR control subjects matched according to sex, age,
and body mass index (BMI), were recruited by advertising
and included in the study after a standard medical exam-
ination and a comprehensive blood and urine screening
(Table 1). Subjects were studied between October 2011
and October 2012. It follows that we were unable to use
the most recent PMR criteria, which were published in
April 2012 [10]. However, the latter criteria are still
provisional and awaiting further validation, and, in the
most recent reviews of PMR, the Chuang criteria are
mentioned on a par with the newer provisional criteria
[6, 7, 10, 16]. In the nature of the case, the two criteria
sets are very similar, but the fact that the demand for a
high sedimentation rate is stricter in the Chuang criteria
implies that the patients in the present study would also
be accepted with the new criteria. The sample size was
calculated by estimating standardized effect sizes from
reported diurnal changes in pain and stiffness in RA
and on the basis of our own experience regarding the
SD of similar visual analogue scale (VAS) measurements
in RA as well as our previous cytokine measurements with
the applied assays in PMR (e.g., [9, 12, 13]). With an α
level of 0.05 and a statistical power of 80 %, a minimum
sample size of seven to ten patients with PMR was
determined.
None of the subjects fulfilled the exclusion criteria:
prior or current use of GCs or other immunosuppressive
drugs; signs of giant cell arteritis, including persistent
headache, visual disturbances, jaw claudication, abnormal
pulsation or wall of temporal artery, and scalp tenderness;
inflammatory diseases other than PMR; infections with
systemic impact; positive blood or urine culture; uncon-
trolled diabetes mellitus or hypertension; neuromuscular
Table 1 Subject characteristics
Patients with PMR (n = 10) Control subjects (n = 7)
Sex, female/male 6/4 4/3
Age, years 76 ± 2.2 71 ± 1.6
BMI, kg m−2 24.0 ± 1.3 26.7 ± 1.2
Blood pressure (systolic/diastolic, mmHg)
Before treatment 143 ± 7/88 ± 6 141 ± 10/86 ± 6
After treatment 147 ± 10/81 ± 3 144 ± 9/85 ± 6
ESR, mm/h
Before treatment 72 ± 8a 10 ± 2
After treatment 21 ± 4b 8 ± 1
CRP, mg/L
Before treatment 56 ± 7a 3 ± 1
After treatment 7 ± 2b 1 ± 0.3
PMR-AS
Before treatment 38 ± 2a 0.2 ± 0.1
After treatment 5 ± 1b 0 ± 0
Abbreviations: BMI body mass index, CRP C-reactive protein, ESR erythrocyte
sedimentation rate, PMR polymyalgia rheumatica, PMR-AS polymyalgia rheumatica
activity score [18]
Values are mean ± SEM. Subjects were studied before treatment and during
the 14th day of prednisolone treatment (20 mg/day)
a Patients vs control subjects, 2P < 0.05
b After vs before treatment, 2P < 0.05
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disease; disturbance of calcium homeostasis; or prior
cancer. In both groups, some subjects, as expected for
their age, were taking medications for, for example,
hypertension, hypercholesterolemia, type 2 diabetes, acid
regurgitation, bladder hyperactivity, or prostatic hyperpla-
sia. Because these medications had no known impact on
study variables, they were continued. Only paracetamol
was allowed as an analgesic, but intake was stopped
the evening before hospitalization. None of the subjects
smoked during the study.
Study design
The study was carried out in compliance with the
Declaration of Helsinki and was approved by the re-
gional ethics committee of Copenhagen (approval number
H-1-2011-060). Informed written consent was obtained
before a subject was included. Both patients and control
subjects were admitted to Rigshospitalet, Copenhagen, for
24 h before treatment and on the 14th day of GC treat-
ment with prednisolone (20 mg taken at 08:00 [6, 7, 16]).
Usually, study of a patient with PMR was followed by
study of a matched control subject. No subjects were stud-
ied in December and January or in June and July. These
facts would minimize any influence of season on the study
outcome. However, of even greater importance in this re-
spect, light conditions in this hospital are controlled and
are the same all year round. On both admissions, subjects
arrived at the hospital at 10:00. Between 10:00 and 10:30,
a small Teflon catheter was inserted into a forearm vein
for blood sampling at 11:00, 12:00, 14:00, 16:00, 19:00,
21:00, 22:00, 23:00, 00:00; 01:00, 02:00, 03:00, 04:00, 05:00,
06:00, 06:30, 07:15, 08:00, 09:00, and 10:00. When neces-
sary at nighttime, a small pencil lamp, directed away from
the patient’s face, was used during the brief blood sam-
pling. However, mostly it was possible to take the samples
while the patients were sleeping. Otherwise, they were told
to close their eyes during the sampling. Symptoms of
global pain and generalized muscle stiffness were assessed
by the patients and the physician using a VAS (0–10 cm) at
12:00, 16:00, 20:00, 04:00, and 08:00. To limit the impact
on the sleeping pattern of the subjects, VAS scores were
not collected from 20:00 to 04:00. The Polymyalgia
Rheumatica Activity Score (PMR-AS) was assessed once
in the morning before and after treatment [12, 18]. Meals
were served at 8:00, 12:00, and 18:00. Subjects were ambu-
lant in the daytime.
Blood samples
Blood was drawn in ethylenediaminetetraacetic acid
tubes and rapidly centrifuged at 1200 rpm and room
temperature for 2 minutes. Plasma was stored at −80 °C
until analysis within 6 months. In separate stock Vacu-
tainer tubes (BD Biosciences, San Jose, CA, USA),
blood was drawn for erythrocyte sedimentation rate
(ESR) measurement.
Analytical methods
Interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-α,
IL-10, IL-1β, and IL-4 were measured using a multiplex
immunoassay method on a Luminex 100 platform (Luminex,
Austin, TX, USA) with specific, high-sensitivity assay
kits (MILLIPLEX high-sensitivity human cytokine mag-
netic bead kit, HSCYTMAG-60SK HSCYTMAG60SPMX13
[premixed]; EMD Millipore, Billerica, MA, USA). Standard
curves were prepared in plasma-analogous matrix contained
in the assay kit. Generally, samples from a patient and a con-
trol subject were analyzed simultaneously, and all assays
were carried out in duplicate and by the same technician.
The ranges of intra- and interassay coefficients of variation
(coefficient of variation [CV], calculated from single deter-
minations) for the cytokine analyses were 7.7–10.6 % and
9.4–15.2 %, respectively. Melatonin was measured by radio-
immunoassay with intra- and interassay CVs of 10 % and
11 %, respectively (BA R-3300; LDN GmbH, Nordhorn,
Germany). Cortisol, with intra- and interassay CVs of 6.3 %
and 10.4 %, respectively, and cross-reactivity of prednisolone
of 4.4 % (KGE008; R&D Systems, Minneapolis, MN, USA),
and C-reactive protein (CRP), with intra- and interassay
CVs of 8.3 % and 6.6 %, respectively (Human Quantikine
DCRP00; R&D Systems), were determined by enzyme-
linked immunosorbent assay. ESR was measured using
the Westergren method (BD Sedi-15; BD Biosciences).
Statistics
Data are expressed as mean ± SEM. In the figures,
smoothed curves drawn using Prism analysis based on
second-order polynomial and four neighboring points
(GraphPad Software, La Jolla, CA, USA) are shown [19].
Statistical analysis was performed using SigmaStat
software (Systat Software, San Jose, CA, USA). Values
of 2P ˂ 0.05 were considered significant in two-tailed
testing. Anthropometric data were evaluated by perform-
ing t tests, unpaired or paired as applicable. Variation with
time during the day was evaluated by one-way analysis of
variance (ANOVA) with repeated measures, as well as by
two-way repeated-measures ANOVA to also evaluate the
effect of either disease (PMR) or treatment (prednisolone)
[20–22]. Differences were located by performing the
Newman-Keuls post hoc test. If compatibility of data with
normal distribution could not be confirmed with large
probability according to the Shapiro-Wilk W test, data
were also analyzed by nonparametric testing (using
the Friedman ANOVA test and the Wilcoxon and
Mann-Whitney U ranking tests for paired and unpaired
data, respectively). However, these tests yielded exactly the
same conclusions as parametric testing, supporting the
robustness of the latter.
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The total AUC for each of the 24-h observation pe-
riods were calculated using the trapezoidal rule, and
effects of disease and treatment were evaluated by
two-way ANOVA. Furthermore, to reduce effects of
random variation of single samples on time course
evaluations, AUCs were also calculated for 3- to 6-h
subintervals of the day, and effects of time, disease, and
treatment were assessed for these subintervals using
ANOVA. However, this approach yielded the same con-
clusions as we obtained from analysis of the raw data.
Finally, Pearson’s or nonparametric Spearman’s correlation
coefficients were calculated as applicable. To limit the dif-
ficult statistical problem of potential mass significance,
correlation analyses were not carried out indiscriminately,
but only according to decisions made in advance of the
study about which relationships would be pertinent to
characterize. An additional way to deal with the problem
would be to adjust P values (e.g., by the Bonferroni
method). However, this is known to cause overcorrection
of unknown magnitude. So, we report the directly deter-
mined P values for individual correlations, abstracting
from the fact that several analyses were carried out.
Results
Baseline anthropometrics, comprising age, BMI, body
temperature (37.1 ± 0.1 vs 36.7 ± 0.2 °C), heart rate (78 ±
5 vs 66 ± 4 beats/minute), and blood pressure did not
differ between untreated patients and control subjects
(Table 1). Before treatment, CRP (56 ± 7 vs 3 ± 1 mg/L),
ESR, and PMR-AS were significantly higher (2P ˂ 0.05)
in patients with PMR than in control subjects (Table 1).
However, after 13 days of prednisolone treatment, patients
had achieved profound clinical remission, as judged by
standard physician assessment as well as on the basis of
markedly reduced PMR-AS scores (Table 1). Furthermore,
after treatment, CRP (7 ± 2 mg/L) and ESR levels had de-
creased markedly in patients, now being within normal
limits in all (CRP) and in six of ten (ESR) subjects, re-
spectively (Table 1).
Diurnal variation of clinical symptoms
In the patients, both global pain and experience of muscle
stiffness attained the highest values in the early morning,
showing a plateau between 04:00 and 08:00 (Fig. 1). Subse-
quently, values decreased significantly (2P ˂ 0.05), reach-
ing a nadir at 16:00 (Fig. 1). Assessment by the physician
mirrored that of the patients (Fig. 1). After treatment with
prednisolone, symptoms were negligible and showed no
diurnal variation (Fig. 1).
Diurnal variation of plasma concentrations of cytokines
and cortisol in untreated patients and control subjects
Concentrations of IL-6, IL-8, and TNF-α (Fig. 2), as well
as of IL-4 and IL-1β (see Additional file 1), but not of
IL-10 (Fig. 3), varied significantly with time in both
groups (2P ˂ 0.05). They peaked in the early morning
between 04:00 and 08:00. Furthermore, concentrations
of all of the above-mentioned cytokines except IL-1β
were significantly higher (2P ˂ 0.05) throughout the 24-h
observation period in patients than in control subjects.
Consequently, 24-h AUCs for all of the cytokines except
IL-1β were significantly larger in patients than in control
subjects (2P ˂ 0.05) (Fig. 4 and Additional file 2).
Cortisol and CRP concentrations also showed diurnal
variation in both groups and were significantly higher in
patients than in control subjects (2P ˂ 0.05) (Fig. 3).
Correspondingly, 24-h AUCs for cortisol were 2137 ±
184 ng/ml × 24 h (patients) and 1253 ± 144 ng/ml × 24 h
(control subjects) (2P ˂ 0.004). However, while cortisol
peaked around 08:00, CRP reached a nadir at this time
point (Fig. 3).
Effects of prednisolone on cytokines and cortisol in plasma
During the 14th day of prednisolone treatment, IL-6,
IL-8, and TNF-α concentrations in both patients and
control subjects were lower than before treatment
Fig. 1 Generalized muscle stiffness and global pain during the day in
ten patients with polymyalgia rheumatica. Symptoms were assessed
both by the patients and by a physician before treatment and during
the 14th day of treatment with 20 mg of prednisolone taken in the
morning. Values are mean ± SEM. Inverted open triangles, Variation
with time in untreated patients (2P < 0.05). Filled squares, Difference
between prednisolone-treated and untreated patients (2P < 0.05).
VAS visual analogue scale
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(2P ˂ 0.05) (Fig. 2). Consequently, 24-h AUCs were also
diminished (2P ˂ 0.05) (Fig. 4). Concentrations of
CRP were also reduced by prednisolone in the patients
(2P ˂ 0.05) (Fig. 3), whereas levels of IL-4 and IL-1β were
not significantly affected (see Additional files 1 and 2). For
cortisol and IL-10 concentrations, an interaction between
prednisolone and time was found in both groups, resulting
in significantly increased levels from about 10:00 to 14:00
(2P ˂ 0.05) (Fig. 3).
Melatonin
In both patients and control subjects, regardless of whether
they were treated with prednisolone, melatonin concentra-
tions showed significant diurnal variation (2P ˂ 0.05) and
Fig. 2 Plasma concentrations of various cytokines monitored for 24 h.
Ten patients with polymyalgia rheumatica (PMR) and seven non-PMR
control subjects were studied before treatment and during the 14th
day of treatment with 20 mg of prednisolone. Values are mean ± SEM.
Smoothed curves are included. Inverted open triangles, Variation with
time in each of the groups (2P < 0.05). Open squares, Difference
between untreated patients and control subjects (2P < 0.05). Filled
squares, Effect of prednisolone (2P < 0.05) in both patients and
control subjects. IL interleukin, TNF tumor necrosis factor
Fig. 3 Plasma concentrations of cortisol, interleukin (IL)-10, and
C-reactive protein (CRP) monitored for 24 h. Ten patients with
polymyalgia rheumatica (PMR) and seven non-PMR control subjects
were studied before treatment and during the 14th day of treatment
with 20 mg of prednisolone. Values are mean ± SEM. Smoothed curves
are included. Inverted open triangles, Variation with time in each of the
groups (2P < 0.05), except for CRP, in prednisolone-treated patients
(not significant). Open squares, Difference between untreated patients
and control subjects (2P < 0.05). Filled squares, Effect of prednisolone
(2P < 0.05) in both patients and control subjects. Filled circle, Effect of
time only in prednisolone-treated groups (interaction) (2P < 0.05)
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peaked around 02:00, about 4 h earlier than cytokine
concentrations (Fig. 5). In untreated patients, concentra-
tions were significantly higher than in control subjects
(2P ˂ 0.05) and were also reduced by prednisolone
treatment (2P ˂ 0.05) (Figs. 4 and 5).
Correlations
The TNF-α peak and 24-h AUC concentrations both
correlated with the peak in patient-reported pain (r = 0.6,
2P ˂ 0.08, and r = 0.7, 2P ˂ 0.03, respectively) as well as
with the peak in patient-reported stiffness (r = 0.6, 2P ˂
0.08, r = 0.8, 2P ˂ 0.006, respectively). The IL-6 24-h AUC
correlated with the average patient-reported pain level
during 04:00–08:00 (r = 0.6, 2P ˂ 0.05). The IL-8 24-h
AUC correlated with the physician-estimated peak pain
(r = 0.6, 2P ˂ 0.05). IL-10 did not correlate significantly
with symptoms. The melatonin peak and 24-h AUC con-
centrations correlated with the TNF-α average level dur-
ing 04:00–06:00 in patients (r = 0.7, 2P ˂ 0.04, and r = 0.6,
2P ˂ 0.07, respectively) and in patients and control sub-
jects combined (r = 0.6, 2P ˂ 0.01, and r = 0.5, 2P ˂ 0.03,
respectively). Various measures of cortisol secretion corre-
lated significantly with measures of IL-6 secretion, but not
of TNF-α secretion, in patients as well as in patients and
control subjects combined (e.g., peak concentration vs
peak concentration and 24-h AUC vs 24-h AUC, r = 0.8
and 2P ˂ 0.006 for all).
Discussion
In the present study, several new important findings that
extend knowledge about PMR were obtained. First, the
previously presumed diurnal variation in key symptoms
has now been documented. In untreated patients pain
and stiffness peak between 04:00 and 08:00 and then de-
cline to a nadir at 16:00. Second, the diurnal variation in
symptoms is paralleled by circadian changes in plasma
concentrations of several proinflammatory and anti-in-
flammatory cytokines, most of which are increased com-
pared with findings in healthy subjects. Third, plasma
melatonin and cortisol concentrations are increased in
patients with PMR throughout the day. Furthermore,
possibly reflecting causal relationships, while the peak
Fig. 4 Total plasma concentration AUCs for the 24-h observation periods (24-h AUCs). Ten patients with polymyalgia rheumatica (PMR) and seven
non-PMR control subjects had melatonin and various cytokines measured before treatment and during the 14th day of treatment with 20 mg of
prednisolone. Values are mean ± SEM. Open squares, Difference between untreated patients and control subjects (2P < 0.05). Filled squares, Effect
of prednisolone (2P < 0.05). IL interleukin
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in melatonin precedes the peak in cytokine concentra-
tions and symptoms by about 4 h, these variables de-
cline when cortisol peaks. Finally, after 13 days of
prednisolone treatment, abolition of symptoms in pa-
tients with PMR is accompanied by marked reductions
in melatonin and cytokine levels around the clock.
It has previously been shown that the morning plasma
concentrations of the proinflammatory cytokines TNF-α,
IL-6, and IL-8 are higher, whereas concentrations of
IL-1β are similar, in patients with PMR compared with
non-PMR control subjects [9, 12–14]. It is a new find-
ing that also concentrations of the anti-inflammatory
cytokines IL-4 and IL-10 are increased in patients with
PMR. Furthermore, it is a new observation that the
above-mentioned differences between patients and control
subjects exist throughout the day (Figs 2, 3, 4 and
Additional file 1). Previously, lack of agreement be-
tween studies regarding the existence of differences in
cytokine concentrations between patients with PMR and
control subjects was tentatively ascribed to differences in
sampling time [11]. However, according to the present
findings, this explanation cannot be sustained. Physical ac-
tivity is known to increase concentrations of several cyto-
kines in plasma [23, 24]. However, differences in physical
activity would not explain the differences in cytokine con-
centrations between groups in the present study. This is
so because during hospitalization the possibilities for exer-
cise were limited, and, if anything, patients with PMR
would be supposed to be less active than control subjects.
Not only are plasma concentrations of many cytokines
markedly higher in patients with PMR than in control
subjects throughout the day, but the present study has
also shown that in both groups concentrations show di-
urnal variation (Fig. 2 and Additional file 1). Previously,
diurnal variation was indicated in a study of nocturnal
cytokine levels in healthy men, the study reporting that
IL-1β and IL-6 were more likely to be above detection
limits during sleep than during preceding wakefulness
[25]. Furthermore, in a study of patients with PMR with
no control subjects, IL-6 showed a diurnal variation com-
parable to the present findings [26]. In contrast, various
other cytokines showed no clear indication of circadian
variation [26]. In RA, diurnal variation in cytokine con-
centrations, albeit less comprehensively than in the
present study of PMR, has been reported and proposed to
be partly responsible for the circadian rhythm of the clin-
ical symptoms [1, 5, 20]. In the present study, often-
requested data [5, 11] documenting a similar diurnal vari-
ation in major symptoms of PMR (i.e., pain and stiffness)
are presented (Fig. 1). It is an intriguing possibility that
also in PMR the circadian variation in these symptoms is
to a great extent caused by a parallel variation in cytokine
levels. Interestingly, in fibromyalgia, which may be con-
fused with RA and PMR but which is a noninflammatory
condition, pain and stiffness do not display circadian
rhythms [27].
Melatonin concentrations in plasma have not previously
been determined in PMR. We found that they display the
same diurnal variation as seen in control subjects (Fig. 5).
However, throughout the day, concentrations in patients
were around two times higher than in control subjects.
Furthermore, they peaked about 4 h before the elevated
cytokine concentrations. These findings are in agreement
with the proposal based on studies in RA that melatonin
is involved in the regulation of the circadian variation in
cytokine concentrations [1, 5]. Melatonin has a variety of
effects on the immune system, which may differ according
to study conditions, such as between cell types and in vivo
vs in vitro [28, 29]. However, in accordance with the above
interpretation, melatonin administration has recently been
shown to enhance the release of both proinflammatory
and anti-inflammatory cytokines under inflammatory
conditions in rats [30]. Also in agreement with an asso-
ciation between enhanced melatonin secretion and
inflammation, in the noninflammatory but painful con-
dition of fibromyalgia, melatonin concentrations are
identical to those of healthy subjects [27]. In RA, higher
circadian melatonin concentrations in a northern com-
pared with a southern European population were asso-
ciated with increasing incidence of the disease with
latitude [31]. It is interesting to note that also the
prevalence of PMR is particularly high in Northern
Europe [6, 7]. An obvious hypothesis is that the increased
prevalence of autoimmune diseases in Northern Europe is
related to the reduced daily light exposure, present at least
Fig. 5 Plasma concentrations of melatonin monitored for 24 h. Ten
patients with polymyalgia rheumatica (PMR) and seven non-PMR
control subjects were studied before treatment and during the 14th
day of treatment with 20 mg of prednisolone. Values are mean ± SEM.
Smoothed curves are included. Inverted open triangle, Variation with time
in each of the groups (2P < 0.05). Open square, Difference between
untreated patients and control subjects (2P< 0.05). Filled diamond, Effect
of prednisolone in the patients (2P< 0.05)
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during wintertime, and consequent increased immunosti-
mulation by melatonin [32].
During the day, the secretion of cortisol is displaced
relative to that of melatonin, and the two hormones have
many mutually opposite effects on the immune system
[1, 33]. Accordingly, in RA, also cortisol has been pro-
posed to participate in the regulation of the diurnal vari-
ation in cytokine secretion and symptoms [1, 3, 34]. While
in RA cytokine concentrations peaking in the night and
early morning may increase cortisol secretion by stimula-
tion of both the hypothalamus and the adrenal medulla,
cortisol may in turn downregulate cytokine expression
[3, 35, 36]. The present study shows that similar relation-
ships may be at play in PMR. Thus, cytokine concentra-
tions peaked somewhat earlier than cortisol concentrations
and declined in parallel with clinical symptoms, when
cortisol levels peaked about 08:00 (Figs. 1, 2 and 3).
Furthermore, administration of prednisolone, a cortisol
analogue, markedly reduced cytokine concentrations and
symptoms throughout the day (Figs. 1, 2, 3 and 4). This is
in accord with and adds to previous findings obtained in
the morning [9, 13, 14]. Our findings also confirm the pre-
vious observation that, in PMR, prednisolone treatment
diminishes IL-6 peak concentration and 24-h AUC [26].
In the patients with PMR in the present study, prednisol-
one diminished melatonin concentrations as well (Fig. 5).
This is in line with the finding that cortisol inhibits mela-
tonin synthesis in the pineal gland [37].
It has been claimed that, in both RA and PMR, cortisol
secretion is inappropriately low in relation to proinflam-
matory status—“the disproportion principle” [38]—and
that this may contribute to the symptoms [3, 11, 36]. Indi-
cating that hypothalamic-pituitary-adrenal axis activation,
albeit less than might be expected from the state of in-
flammation, may nevertheless be present, we previously
found higher morning concentrations of both adrenocor-
ticotropic hormone and cortisol in patients with PMR
than healthy subjects [39]. The fact that researchers in
other studies had not found such differences was ex-
plained by lower disease activity and longer disease onset
to study duration in those studies [39]. The present study
extends our previous findings by showing that, in PMR,
cortisol concentrations may be increased throughout
the day (Fig. 3), resulting in a doubling of 24-h cortisol
AUC in patients compared with control subjects.
In RA, administration of GCs prior to the circadian
flare in inflammatory activity has been proven to be ad-
vantageous compared with traditional administration in
the morning [5, 15, 40–42]. The present finding in PMR
of a similar diurnal variation in cytokines and symptoms
indicates that also in PMR adaptation of the timing of
GC administration to the chronobiology of the disease
would optimize the treatment. In fact, preliminary ex-
periments have been reported to show positive outcomes
of such an approach, with reductions in IL-6 levels and
morning stiffness being more pronounced upon admin-
istration of prednisolone in the night than in the morn-
ing [26].
Although the cross-reactivity of prednisolone in the
cortisol assay is only 4.4 %, the high cortisol levels seen
in both patients and control subjects upon prednisolone
administration in the morning (Fig. 3) most likely reflect
comeasurement of high prednisolone concentrations.
Still, previously, increases in early morning peak cortisol
concentrations have been found in patients with RA
upon nighttime prednisone administration, even after cor-
recting for cross-reactivity by direct measurement of drug
levels [22]. It was speculated that the enhanced nocturnal
rise in plasma cortisol reflected a change in relationship
between the hypothalamic-pituitary-adrenal axis and im-
mune system activation [22].
In the present study, concentrations of the anti-
inflammatory cytokine IL-10 also were increased by
prednisolone (Fig. 3). On the basis of previous studies of
lipopolysaccharide-stimulated IL-10 secretion in whole
blood in vitro, it has been concluded that cortisone ad-
ministration in vivo has little effect on IL-10 secretion
[35]. However, the presented data allow the conclusion
that GC in fact does enhance IL-10 secretion, because
secretion decreased in control experiments but not upon
cortisone administration [35]. Albeit not confirmed by
our data, it is interesting to note that, on the basis of
correlation analysis, a favorable role of IL-10 in PMR
has been proposed [43]. CRP can be considered an in-
flammatory cytokine regulated by circulating IL-6 and
other cytokines [44]. In contrast to the view that acute-
phase CRP values show no diurnal variation [45], in the
present study in untreated patients with PMR, CRP showed
a clear circadian rhythm with a nadir at 08:00 (Fig. 3). This
time course seems compatible with the delay inherent in
intranuclear expression stimulation and in the long plasma
half-life of CRP.
Conclusions
The present study documents diurnal variation of key
symptoms in PMR and points out potentially underlying
pathophysiological mechanisms. Thus, in PMR concentra-
tions of melatonin, several pro- and anti-inflammatory cy-
tokines and of cortisol are increased throughout the day
and show circadian variation, as also seen in healthy sub-
jects. The time courses are compatible with the view that,
in PMR, as proposed also for RA, melatonin stimulates
cytokine production, which in turn accounts at least partly
for the clinical symptoms, while overall cortisol downre-
gulates cytokine production and symptoms. The view is
supported by the finding that, in PMR, prednisolone di-
minishes levels of both melatonin and proinflammatory
cytokines while abolishing symptoms throughout the day.
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In addition, stimulation of IL-10 secretion may to some
extent mediate the anti-inflammatory effects of prednisol-
one. Finally, in untreated PMR, CRP also shows diurnal
variation. These findings support future use of chrono-
therapy in PMR and encourage study of circadian varia-
tions in other inflammatory autoimmune diseases.
Additional files
Additional file 1: Figure S6. Plasma concentrations of IL-4 and IL-1β
monitored for 24 h. Ten patients with PMR and seven non-PMR control
subjects were studied before treatment and during the 14th day of treatment
with 20 mg of prednisolone. Values are mean ± SEM. Smoothed curves
are included. Open inverted triangles, Variation with time in all groups
(2P < 0.05), except for prednisolone-treated control subjects. Open boxes,
Difference between untreated patients and control subjects (2P < 0.05).
Filled diamonds, Effect of prednisolone in control subjects (2P < 0.05).
(DOCX 245 kb)
Additional file 2: Figure S7. Total areas under the plasma concentration
curve for 24-h measurements of IL-1β (24-h AUCs). Ten patients with PMR
and seven non-PMR control subjects had IL-1β measured before treatment
as well as during the 14th day of treatment with 20 mg of prednisolone.
Values are mean + SEM. Filled squares, Effect of prednisolone (2P < 0.05).
(DOCX 49 kb)
Abbreviations
ANOVA, analysis of variance; BMI, body mass index; CRP, C-reactive
protein; CV, coefficient of variation; ESR, erythrocyte sedimentation rate;
GC, glucocorticoid; IL, interleukin; PMR, polymyalgia rheumatica; PMR-AS,
Polymyalgia Rheumatica Activity Score; RA, rheumatoid arthritis; TNF, tumor
necrosis factor; VAS, visual analogue scale
Acknowledgements
The Department of Statistics of the Faculty of Health Sciences, University of
Copenhagen, is thanked for statistical advice.
Funding
The study was supported by The Capital Region of Denmark, the Foundation
for Health Research, and the Copenhagen Muscle Research Center. The funding
bodies were not involved in any aspects of the study.
Availability of data and materials
Data and any needed further information will be forwarded upon request.
Authors’ contributions
HG conceived of and designed the study, recruited the patients, and examined
them and the control subjects clinically. HG also participated in the experimental
investigations and in the analysis of the data and wrote the manuscript. LK
contributed to the design of the study, carried out all chemical analyses, and
participated in the experimental investigations and the analysis of the data. LK
critically revised the manuscript. Both authors approved the manuscript before
submission, and both are accountable for its content.
Competing interests
The authors declare that they have no financial or nonfinancial competing
interests.
Ethics approval and consent to participate
The study complied with the Declaration of Helsinki and was approved by the
research ethics committee of Copenhagen (approval number H-1-2011-060).
Informed written consent was obtained before each subject was included.
Received: 14 March 2016 Accepted: 6 July 2016
References
1. Cutolo M, Seriolo B, Craviotto C, Pizzorni C, Sulli A. Circadian rhythms in RA.
Ann Rheum Dis. 2003;62:593–6.
2. Cutolo M, Maestroni GJM. The melatonin-cytokine connection in rheumatoid
arthritis. Ann Rheum Dis. 2005;64:1109–11.
3. Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications
for pathophysiology and therapeutic management. Arthritis Rheum.
2007;56:399–408.
4. Spies CM, Straub RH, Cutolo M, Buttgereit F. Circadian rhythms in
rheumatology – a glucocorticoid perspective. Arthritis Res Ther.
2014;16 Suppl 2:S3.
5. Buttgereit F, Smolen JS, Coogan AN, Cajochen C. Clocking in: chronobiology in
rheumatoid arthritis. Nat Rev Rheumatol. 2015;11:349–56.
6. Nesher G. Polymyalgia rheumatica – diagnosis and classification. J Autoimmun.
2014;48–49:76–8.
7. Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet. 2013;381:63–72.
8. Pipitone N, Salvarani C. Update on polymyalgia rheumatica. Eur J Int Med.
2013;24:583–9.
9. Kreiner F, Galbo H. Insulin sensitivity and related cytokines, chemokines, and
adipokines in polymyalgia rheumatica. Scand J Rheumatol. 2010;39:402–8.
10. Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M,
Salvarani C, et al. 2012 provisional classification criteria for polymyalgia
rheumatica: a European League Against Rheumatism/American College of
Rheumatology collaborative initiative. Ann Rheum Dis. 2012;71:484–92.
11. Spies CM, Cutolo M, Straub RH, Burmester GR, Buttgereit F. More night than
day – circadian rhythms in polymyalgia rheumatica and ankylosing spondylitis.
J Rheumatol. 2010;37:894–9.
12. Kreiner F, Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized
controlled trial. Arthritis Res Ther. 2010;12:R176.
13. Kreiner F, Langberg H, Galbo H. Increased muscle interstitial levels of
inflammatory cytokines in polymyalgia rheumatica. Arthritis Rheum.
2010;62:3768–75.
14. Cutolo M, Montecucco CM, Cavagna L, Caporali R, Capellino S, Montagna P,
et al. Serum cytokines and steroid hormones in polymyalgia rheumatica
and elderly-onset rheumatoid arthritis. Ann Rheum Dis. 2006;65:1438–43.
15. Buttgereit F, Gibofsky A. Delayed-release prednisone – a new approach to
an old therapy. Expert Opin Pharmacother. 2013;14:1097–106.
16. Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al.
2015 recommendations for the management of polymyalgia rheumatica:
a European League Against Rheumatism/American College of Rheumatology
collaborative initiative. Arthritis Rheumatol. 2015;67:2569–80.
17. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia
rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med.
1982;97:672–80.
18. Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann
Rheum Dis. 2004;63:1279–83.
19. Savitzky A, Golay MJE. Smoothing and differentiation of data by simplified
least squares procedures. Anal Chem. 1964;36:1627–39.
20. Arvidson NG, Gudbjornsson B, Elfman L, Rydén AC, Totterman TH, Hallgren R,
et al. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann
Rheum Dis. 1994;53:521–4.
21. Norrelund H, Gravholt CH, Englaro P, Blum WF, Rascher W, Christiansen JS,
et al. Increased levels but preserved diurnal variation of serum leptin in
GH-deficient patients: lack of impact of different modes of GH administration.
Eur J Endocrinol. 1998;138:644–52.
22. Clarke LL, Jessop DS, Hunt LP, Straub RH, Perry MG, Kirwan JR. Alleviation of
morning joint stiffness by low-dose prednisone in rheumatoid arthritis is
associated with circadian changes in IL-6 and cortisol. Int J Clin Rheumatol.
2011;6:241–9.
23. Suzuki K, Nakaji S, Yamada M, Totsuka M, Sato K, Sugawara K. Systemic
inflammatory response to exhaustive exercise: cytokine kinetics. Exerc
Immunol Rev. 2002;8:6–48.
24. Nieman DC, Davis JM, Henson DA, Gross SJ, Dumke CL, Utter AC, et al.
Muscle cytokine mRNA changes after 2.5 h of cycling: influence of
carbohydrate. Med Sci Sports Exerc. 2005;37:1283–90.
25. Gudewill S, Pollmächer T, Vedder H, Schreiber W, Fassbender K, Holsboer F.
Nocturnal plasma levels of cytokines in healthy men. Eur Arch Psychiatry
Clin Neurosci. 1992;242:53–6.
26. Zakout SA, Clarke LL, Jessop D, Straub RH, Kirwan JR. Circadian variation in
plasma IL-6 and the role of modified-release prednisone in polymyalgia
rheumatica. Int J Clin Rheumatol. 2014;9:431–9.
Galbo and Kall Arthritis Research & Therapy  (2016) 18:174 Page 9 of 10
27. Klerman EB, Goldenberg DL, Brown EN, Maliszewski AM, Adler GK. Circadian
rhythms of women with fibromyalgia. J Clin Endocrinol Metab. 2001;86:1034–9.
28. Calvo JR, González-Yanes C, Maldonado MD. The role of melatonin in the
cells of the innate immunity: a review. J Pineal Res. 2013;55:103–20.
29. Lin GJ, Huang SH, Chen SJ, Wang CH, Chang DM, Sytwu HK, et al.
Modulation by melatonin of the pathogenesis of inflammatory autoimmune
diseases. Int J Mol Sci. 2013;14:11742–66.
30. Effenberger-Neidnicht K, Brencher L, Broecker-Preuss M, Hamburger T,
Petrat F, Groot H, et al. Immune stimulation by exogenous melatonin
during experimental endotoxemia. Inflammation. 2014;37:738–44.
31. Cutolo M, Maestroni GJM, Otsa K, Aakre O, Villagio B, Capellino S, et al. Circadian
melatonin and cortisol levels in rheumatoid arthritis patients in winter time:
a north and south Europe comparison. Ann Rheum Dis. 2005;64:212–6.
32. Cutolo M, Villagio B, Otsa K, Aakre O, Sulli A, Seriolo B. Altered circadian
rhythms in rheumatoid arthritis patients play a role in the disease’s
symptoms. Autoimmun Rev. 2005;4:497–502.
33. Vishwas DK, Mukherjee A, Haldar C. Melatonin improves humoral and
cell-mediated immune responses of male golden hamster following
stress induced by dexamethasone. J Neuroimmunol. 2013;259:17–25.
34. Cutolo M, Sulli A, Pizzorni C, Secchi ME, Soldano S, Seriolo B, et al. Circadian
rhythms. Glucocorticoids and arthritis. Ann N Y Acad Sci. 2006;1069:289–99.
35. Petrovsky N, Harrison LC. Diurnal rhythmicity of human cytokine production.
J Immunol. 1997;158:5163–8.
36. Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS, et
al. Circadian relationships between interleukin (IL)-6 and hypothalamic-
pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism
in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab.
1997;82:1279–83.
37. López-Patiño MA, Gesto M, Conde-Sieira M, Soengas JL, Miguez JM. Stress
inhibition of melatonin synthesis in the pineal organ of rainbow trout
(Oncorhynchus mykiss) is mediated by cortisol. J Exp Biol. 2014;217:1407–16.
38. Straub RH, Buttgereit F, Cutolo M. Alterations of the hypothalamic-pituitary-
adrenal axis in systemic immune diseases – a role for misguided energy
regulation. Clin Exp Rheumatol. 2011;29(5 Suppl 68):S23–31.
39. Kreiner FF, Galbo H. Activity of the neuroendocrine axes in patients with
polymyalgia rheumatic before and after TNF-α blocking etanercept treatment.
Arthritis Res Ther. 2012;14:R186.
40. Arvidson NG, Gudbjornsson B, Larsson A, Hallgren R. The timing of
glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis.
1997;56:27–31.
41. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gramnica-Ihle E,
et al. Efficacy of modified release versus standard prednisone to reduce
duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1):
a double-blind, randomized controlled trial. Lancet. 2008;371:205–14.
42. Buttgereit F, Mehta D, Kirwan J, Szechinski J, Boers M, Alten RE. Low-dose
prednisone chronotherapy for rheumatoid arthritis: a randomized clinical
trial (CAPRA-2). Ann Rheum Dis. 2013;72:204–10.
43. Straub RH, Herfarth HH, Rinkes B, Konecna L, Glück T, von Landenberg P, et al.
Favorable role of interleukin 10 in patients with polymyalgia rheumatica. J
Rheumatol. 1999;26:1318–25.
44. Lau DCW, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links
between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol.
2005;288:H2031–41.
45. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest.
2003;111:1805–12.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Galbo and Kall Arthritis Research & Therapy  (2016) 18:174 Page 10 of 10
